Merck’s nine-valent HPV vaccine adopts a three-dose immunization program and is suitable for the prevention of cervical cancer (HPV) caused by HPV16, 18, 31, 33, 45, 52 and 58, HPV6, 11, 16, 18, 31, 33, 45, Cervical intraepithelial neoplasia (CIN1/2/3 grade) and cervical adenocarcinoma in situ (AIS) due to types 52 and 58, and HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 persistent infection.
Cervical cancer is one of the common gynecological malignancies.In 2020, among women aged 15-44 in China, the incidence and mortality of cervical cancer ranked third among female tumors.
in China,About 98% of cervical cancers are caused by high-risk HPV typesThe most susceptible high-risk HPV types in Chinese women are HPV16, 52, and 58.
As women age, women’s ability to clear new and previous HPV infections decreases, making them more susceptible to persistent HPV infection and cervical cancer risk.
Professor Qiao Youlin from the School of Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College pointed out that,Adolescent girls are vaccinated against HPV, which is easy to stimulate a better immune response.
Studies have shown that the HPV vaccine also provides good protection for women who have already had sex.
